CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-23). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 1427 · Search date 2026-07-23 · Methodology v0.6

Somnox Sleep Robot,
does it really help with Improved sleep onset, sleep maintenance, and sleep efficiency in chronic insomnia through breathing-rhythm synchronization?

30-Second Summary
D
Evidence Grade D · 28 · Safety unknown
The device may feel comforting, but improved sleep outcomes in chronic insomnia have not been demonstrated
What the
research shows
Somnox is rated D. A trial randomized 44 adults with insomnia to three weeks of robot use or a waitlist and found no significant improvement in insomnia severity, sleep-onset latency, wake after sleep onset, total sleep time, or sleep efficiency by either sleep diary or actigraphy. This is one small null trial, so the grade is D with 28 points rather than F, which would require repeated refutation.
What the
ads claim
A plausible story that movements mimicking slow breathing may reduce arousal is expanded into treatment of chronic insomnia. Current clinical data do not connect the mechanism or comfort with objective sleep improvement.
*

Useful facts when choosing a product

  • Somnox is a cushion-like device held in bed that uses sounds and movements to mimic slow breathing.
  • The pivotal trial evaluated daily home use for three weeks with both sleep diaries and wrist actigraphy.
  • It lacks drug adverse effects, but discomfort, sleep disruption, device reliance, and cost are possible, and evidence does not support replacing cognitive behavioral therapy.
Gap Measurement · Verdict 1427 · D 28
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Støre 2023 randomized 44 adults with insomnia to three weeks of Somnox use or a waitlist. The primary Insomnia Severity Index outcome and sleep-diary and wrist-actigraphy measures of sleep-onset latency, wake after sleep onset, total sleep time, and sleep efficiency were all nonsignificant. An earlier repeated ABA study in four people found marginal diary and actigraphy changes, sometimes in the direction of deterioration, and mixed effects overall.

02

Why this is classified as D (28)

Direct randomized evidence consists of one small 44-person trial with no significant effect on any key sleep outcome. Sparse null evidence yields D with 28 points; the absence of repeated large trials precludes F.

Counterpoint. It may be a personally comforting relaxation aid, but it should not replace cognitive behavioral therapy for insomnia, the evidence-based first-line treatment.

Rejudgment record. New verdict — Applied boundary rule ② for sparse null randomized evidence because a 44-person waitlist-controlled trial found no significant benefit for insomnia severity or diary and actigraphy measures of sleep onset, maintenance, total sleep time, and efficiency; F was excluded because refutation is not repeated

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Improved sleep onsetDDiary and actigraphy sleep-onset latency were nonsignificant in the randomized trial.
Improved sleep maintenanceDWake after sleep onset and total sleep time showed no significant between-group improvement.
Improved sleep efficiencyDBoth subjective and objective sleep efficiency were null, based on one small trial.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Støre SJ et al. 2023Randomized waitlist-controlled trial22Somnox loaned devices but reportedly had no role in design, analysis, or publicationISI, sleep-onset latency, wake after sleep onset, total sleep time, and sleep efficiencyAfter three weeks, neither ISI nor any diary or actigraphy sleep variable differed significantly between groups.Pivotal direct randomized evidence; small and null
Støre SJ et al. 2022Repeated ABA single-case study4Somnox loaned devices; reported as independent researchSleep diary, actigraphy, and insomnia and arousal questionnairesObjective and diary differences were marginal and sometimes worse, with mixed effects overall.Very small exploratory evidence
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-07-23).

Støre SJ, Tillfors M, Wästlund E, et al. The effects of a sleep robot intervention on sleep, depression and anxiety in adults with insomnia-A randomized waitlist-controlled trial. J Sleep Res. 2023;32(3):e13758. PMID: 36285420. DOI: 10.1111/jsr.13758.
checked
Støre SJ, Tillfors M, Wästlund E, Angelhoff C, Norell Clarke A. Technically sleeping? A clinical single-case study of a commercial sleep robot. Front Psychol. 2022;13:919023. PMID: 36600701. PMCID: PMC9807031. DOI: 10.3389/fpsyg.2022.919023.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-23 · Corrections: none

Cite this verdict

Somnox Sleep Robot x improved sleep onset, maintenance, and efficiency in chronic insomnia Evidence Grade D card
[Chamgap] Somnox Sleep Robot x improved sleep onset, maintenance, and efficiency in chronic insomnia — Evidence Grade D·28. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/sleep/somnox-sleep-robot-chronic-insomnia-sleep-outcomes/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.